CHILDRENS HOSPITAL OF ORANGE COUNT
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $13.5M
- Transactions
- 2,677
- Companies
- 40
- Average per transaction
- $5,036
Who reported the payments
| Pfizer | $2,775,359 |
| Jazz Pharmaceuticals Inc. | $1,129,097 |
| Ultragenyx Pharmaceutical Inc. | $871,211 |
| Biomarin Pharmaceutical Inc. | $771,139 |
| Vertex | $645,898 |
| Sanofi | $590,398 |
| Masimo Corporation | $566,721 |
| Novartis | $478,247 |
| Merck | $471,030 |
| Servier Pharmaceuticals LLC | $352,299 |
| Astellas Pharma Global Development | $313,191 |
| Takeda Pharmaceuticals U.S.A., Inc. | $253,210 |
| Chiesi USA, Inc. | $217,891 |
| AbbVie | $213,782 |
| Eli Lilly | $178,209 |
| Smith+Nephew | $170,640 |
| Zevra Therapeutics Inc | $164,603 |
| Novo Nordisk AS | $135,983 |
| Mallinckrodt Enterprises LLC | $134,338 |
| Paratek Pharmaceuticals, Inc. | $128,641 |
| UCB SA | $123,229 |
| Neuraxis, Inc. | $119,098 |
| Boehringer Ingelheim | $118,001 |
| Mallinckrodt Hospital Products Inc. | $115,840 |
| Mannkind Corporation | $114,547 |
| Agios Pharmaceuticals, Inc. | $109,886 |
| Melinta Therapeutics, LLC | $107,816 |
| Immedica Pharma US, Inc. | $101,997 |
| Abbott | $92,500 |
| Incyte Corporation | $76,145 |
| Biogen | $72,501 |
| Medtronic | $69,820 |
| Monteris Medical Corporation | $69,647 |
| Amgen | $68,905 |
| Sanofi US Services Inc. | $65,252 |
| Gilead | $65,011 |
| Janssen Research & Development, LLC | $64,581 |
| Astellas US Technologies | $57,117 |
| Regeneron | $57,111 |
| Cook Research Incorporated | $54,730 |